Business Context and Reporting Period
This Form 8-K is a current report filed by Leap Therapeutics, Inc. (not Cypherpunk Technologies Inc.) on March 18, 2020, regarding events occurring on March 17, 2020. The filing addresses significant executive leadership changes and board composition updates effective April 1, 2020.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
- CEO Resignation: Christopher K. Mirabelli, Ph.D., resigned as President and CEO effective April 1, 2020. He will remain as Chairman of the Board and lead research and development efforts.
- CEO Appointment: Douglas E. Onsi, previously CFO, Treasurer, and Secretary, was appointed President and CEO effective April 1, 2020. He was also appointed as a Class I Director.
- Director Resignation: John Littlechild resigned as a Class I Director and from all Board committee positions effective immediately.
Compensation, Outlook, and Risks
Compensation Adjustments for New CEO (Douglas E. Onsi):
- Base Salary: Increased to $550,000 annually.
- Incentive: Annual opportunity equal to 50% of base salary.
- Equity Grants:
- 500,000 stock options (exercise price based on March 17, 2020 close; 3-year monthly vesting).
- 660,606 restricted stock units (cliff vest after 3 years or upon change of control).
- Severance: Expanded to include 18 months of base salary and COBRA healthcare reimbursement upon termination without cause or for good reason.
Outlook and Risks: The filing states there are no disagreements regarding the resignation of Director John Littlechild. No specific business outlook, risks, or contingencies beyond the leadership transition are detailed in this report.
Investor Verification Checklist
- Verify the effective date of the leadership transition (April 1, 2020).
- Review the total equity value granted to the new CEO based on the March 17, 2020 stock price.
- Confirm the continued role of the outgoing CEO in R&D and as Board Chairman.
- Check subsequent filings for the impact of these changes on the company's strategic direction.